Mon, Dec 22, 2014, 12:15 AM EST - U.S. Markets open in 9 hrs 15 mins

Recent

% | $
Quotes you view appear here for quick access.

SAVIENT PHARM INC Message Board

  • lempe39398 lempe39398 Aug 27, 2013 2:06 PM Flag

    LOL Ferrari updated his profile, look at what he says. I hope this is the case of broken clock being right twice a day

    "Operational Excellence: Implemented the first cost containment measures, clinical programs and an aggressive pricing program, setting Savient to being a profitable company by the end of 2014"

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lempe: As soon as SVNT correctly reprices K to around $10,000/dose or higher 3Q13 SVNT will be immediately profitable by YE 2014......They guided sufficient cash for approx another 12 months 2Q13.......In just a few months analysts will have rev estimates of around $125 mil for 2014.....

      Sentiment: Strong Buy

    • He also excelled in "full P&L leadership"..... By the end of 2014, SVNT might be profitable but in the hands of its creditors.
      ------------------------------------------------------------------------------------------------------------------------------------
      Louis Ferrari's Summary

      PRESIDENT/CEO/GENERAL MANAGER – PHARMA/BIOTECH INDUSTRY
      Diverse commercial and clinical leadership experience in functional disciplines from sales and marketing to clinical and finance, most recently attaining level of President/CEO for publicly traded biopharm company.
       Growth Strategy: Developed alternative use drug indications to expand patient population...more needed
       Operational Excellence: Implemented the first cost containment measures, clinical programs and an aggressive pricing program, setting Savient to being a profitable company by the end of 2014. Member of J&J owned Ortho-BioTech company's Leadership Operations Committee. Thorough understanding of the clinical and commercial regulatory environment and its impact on internal operations.
       Financial Management: Full P&L leadership. Restructured convertible notes to senior secured notes to generate $44 million.
       Personal Philosophy: Dedication to help improve the quality of life of patients, and make a positive difference in the lives of their families and care givers.
       Board Experience: Member of J&J's Ortho-Biotech and post-merger Centocor Ortho-Biotech Boards developing corporate and brand strategies
      Sales&Marketing,Clinical affairs both US and Ex-US

      Specialties: Pharmaceutical Sales and Marketing.
      ------------------------------------------------------------------------------------------------------------------------------------

    • "profitable company by the end of 2014"

      Do we need to know more from the former CEO?
      And he has not sold his shares.

      Sentiment: Strong Buy

 
SVNTQ
0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.